AEON Biopharma, Inc. (NASDAQ:AEON) to Post Q1 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts

AEON Biopharma, Inc. (NASDAQ:AEON) – Equities research analysts at HC Wainwright increased their Q1 2024 EPS estimates for shares of AEON Biopharma in a research note issued on Wednesday, April 17th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.31) for the quarter, up from their prior forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.18) EPS and FY2025 earnings at ($1.16) EPS.

AEON Biopharma Trading Down 28.7 %

Shares of AEON opened at $4.66 on Friday. The firm has a 50-day moving average price of $10.55 and a 200 day moving average price of $7.78. AEON Biopharma has a 52-week low of $3.37 and a 52-week high of $17.17.

AEON Biopharma (NASDAQ:AEON) last announced its earnings results on Friday, March 29th. The company reported ($0.71) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On AEON Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of AEON Biopharma by 8.3% during the 4th quarter. Vanguard Group Inc. now owns 209,785 shares of the company’s stock valued at $1,510,000 after purchasing an additional 16,091 shares in the last quarter. Northern Trust Corp boosted its position in shares of AEON Biopharma by 53.4% during the 4th quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after purchasing an additional 17,341 shares in the last quarter. Formidable Asset Management LLC bought a new position in shares of AEON Biopharma during the 3rd quarter valued at about $360,000. Finally, Atalaya Capital Management LP bought a new position in shares of AEON Biopharma during the 3rd quarter valued at about $19,827,000. Institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.